Artemether–lumefantrine treatment failure despite adequate lumefantrine day 7 concentration in a traveller with Plasmodium falciparum malaria after returning from Tanzania

Malaria Journal

Case Report

Lillemor Karlsson¹  Elda Sparrelid²  Josea Rono³  Johan Ursing⁴  Thomas Tolfvenstam⁴  Anna Färnert⁴  Niklas Lindegårdh⁵ 

[1] Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, SE-171 76, Stockholm, Stockholm, Sweden;Infectious Diseases Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;Infectious Diseases Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden;Department of Infectious Diseases, Karolinska University Hospital, SE-171 76, Stockholm, Stockholm, Sweden;Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand;Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK;

关键词: Malaria;    P. falciparum;    Artemisinin;    Lumefantrine;    Sensitivity;    non-immune;   

DOI  :  10.1186/1475-2875-11-176

 received in 2012-03-22, accepted in 2012-05-25,  发布年份 2012

来源: Springer

【 摘 要 】

Artemether-lumefantrine is currently first-line therapy of Plasmodium falciparum malaria in many countries. This report describes a treatment failure despite adequate drug concentrations in a traveller returning from sub-Saharan Africa. Genotyping confirmed recrudescence and suggested reduced sensitivity. Potential sub-optimal effect of artemether-lumefantrine highlights the need to follow non-immune individuals the weeks after treatment.

【 授权许可】

CC BY   
© Färnert et al.; licensee BioMed Central Ltd. 2012